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ABSTRACT OF CAPSTONE

HEPATOCELLULAR CARCINOMA AMONG KENTENCKY RESIDENTS FROM
1995 TO 2011: RISK FACTORS AND SURVIVABILITY

Introduction: Hepatocellular carcinoma incidence and mortality rates are
the rise in the United States and in Kentucky as well. According to the National
Cancer Institute, there will be an estimated 40,710 new cases of liver and
intrahepatic bile duct cancer and 28,920 deaths in 2017, with than 20% of 5years survivors 1. The numbers of new cases expected by year 2030 is 37,574 2.
The aim of this capstone is to assess the risk factors of late-stage diagnosis and
survivability in Kentucky.
Methods: A combined dataset from the Kentucky Cancer Registry and the
Behavioral Risk Factor Surveillance System was used to perform a descriptive
statistics, a logistic regression and a Cox proportional-hazards regression.
Results: Of the 2,205 cases analyzed, 72.1% were males, 90.2% of
white/other ethnicity, 41.1% were married and lived mostly in urban (59.5%0 and
non-Appalachian region (72.1%). Their mean age at diagnosis was 64.1 years
and most were diagnosed between 2005 and 2009 (81.5%) with late-stage
(41.9%) and did not receive any treatment (55.3%). Our results show that black
race (OR=1.5; 95% CI 1 – 2.1), gender*age interaction (male ≥ 50 years
iii

(OR=1.3; 95% CI 1.2 – 3)), uninsured status (OR=1.6; 95% CI: 1.1 – 2.5), date of
diagnosis before 2000 (O%=1.8; 95%CI: 1.3 – 2.5) and residence in counties
with higher levels of binge drinking proportion (OR=1.03 (1 – 1.1) increased the
risk of HCC late-stage diagnosis in this Kentucky report. Appalachia residence
and single status were not associated with late-stage.
HCC mean survival time in this series was 12.4 months. The mean overall
survival rates for the study period were 12.9%, 24.1% and 17.2% in men, preand postmenopausal women, respectively. Mean specific survival rates were
34.3%, 34.5% and 37.1% in men, pre-and postmenopausal women, respectively.
Early-stage at diagnosis, treatment and younger age were associated with better
overall survival. Men and postmenopausal women had 40% increased risk of allcause mortality (p=0.06). Cause-specific survival was improved by non-smoking
status, recent year of diagnosis, early stage at diagnosis and treatment.
Postmenopausal women had an increased risk for both all cause (OR=2.2;
95%CI: 0.9 – 5.7) and liver cancer specific mortality (OR=1.7; 95%CI: 0.4 – 3.7),
compared to premenopausal women, when parity is added to the covariates.
Conclusions: HCC Late-stage diagnosis was impacted by race, age,
gender, insurance status and county-level binge drinking while non-smoking
status, female gender, early stage and treatment improved survival. These
results highlight the need to increase healthcare access and HCC awareness in
this rural state where poverty is high and education levels are lower than average
to decrease the burden of HCC and improve survival.
KEYWORDS: hepatocellular carcinoma; late-stage of diagnosis; risk
factors; survival; menopausal status; gender difference; Kentucky.
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I.

CHAPTER 1: INTRODUCTION

Background of the project
Hepatocellular carcinoma (HCC) is the most common primary liver cancer.
Incidence and mortality rates vary according to sex and geographic areas. Worldwide,
liver cancer is the fifth and seventh most common cancer in men and women
respectively, while being the second and sixth leading cause of cancer death in men
and women respectively3.
Although HCC incidences and mortality rates are highest in the East and SouthEast Asia and in Middle and Western Africa, rates are consistently increasing in the
developed countries of Europe and North America as well, raising a concern about the
public health consequences of the increase4,5. The National Cancer Institute (NCI)
estimated 35,646 new cases and 24,550 deaths from liver and intrahepatic bile duct
cancer in the United States for the year 2015, and a 5-year survival rate of 17.2% for
the period 2005-20116. In Kentucky, both incidence and mortality rates of the cancer of
the liver and bile duct significantly rose between 2008 and 2012 with an annual
percentage change (APC) of 5.0% and 1.9%, respectively 7,8.
In the United States, HCC incidence rates have been steadily increasing. They
tripled between 1975 and 2005 (from 1.6 per 100,000 to 4.9 per 100,000) with most of
the increase occurring after 1980 and men having a steady 3-fold higher incidence
compared to women9. Between 1992 and 2005, the increase was mostly seen in
middle-aged black, Hispanic, and white males9. More recently, an increase of 18.5%
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was observed with an APC of 3.5%, even with the histologic confirmation of HCC which
likely eliminates cases counted by previous reports. The racial and age disparity is still
present with larger increases in whites, black and persons aged 50-59 years with an
APC of 3.8%, 4.8% and 9.1% respectively10.
Several risk factors have been identified for HCC. Besides male gender and
geographic provenance, other known risk factors are chronic hepatitis B (HBV) and
hepatitis C (HCV) viral infections, alcohol consumption, tobacco smoking
obesity/diabetes, and aflatoxin exposure9,11–14.
HCC mortality rates have been increasing as well. From 1992 to 2005, HCC
overall mortality rates increased with an APC of 1.6%10. A Surveillance, Epidemiology,
and End Results (SEER) investigation found an increase in mortality rates between
1992 and 2005 rising significantly from 3.1 per 100,000 to 5.1 per 100,000 with an APC
of 4.3%9. Between 1969 and 2011, the increase was almost twofold for males and 50%
for females with all ethnic minority groups having higher rates than whites15.
Survival rates are usually low and can be influenced by several factors. A New
York City study investigating the overall survival (OS) of Hispanic patients compared to
other ethnic groups found that Hispanics had an OS of 16.3 months, not significantly
different from the 14 months for non-Hispanic whites and 17.3 months for non-Hispanic
blacks16. Although the survival improves with early stage at diagnosis, Hispanic patients
did not have worse survival compared to the other ethnic groups. A survival analysis of
SEER data between 1973 and 2010 found that women have a better OS than men,
even though the OS was still low (11 months and 10 months). Interaction between sex
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and ethnicity had been investigated and women aged less than 55 years had better
survival than men across all ethnic groups but Hispanic17.
Purpose of the study
This study used secondary surveillance data routinely collected by the Kentucky
Cancer Registry (KCR) and Behavioral Risk Factor Surveillance System (BRFSS)
county-level data. This capstone project analyzed these data and provided the material
for two papers to be submitted for publication in peer-reviewed journals. The objective
of the first paper (chapter 3) was to describe risk factors of late stage HCC in Kentucky.
The objective of the second paper (chapter 4) was to identify the factors associated with
better long-term survival among HCC cases. The results derived from this research may
be used to issue recommendations to improve the management of HCC and lessen its
burden in Kentucky.
Statement of the problem
The global burden of HCC is increasing in the United States. The last four
decades have seen an increase in both the incidence and mortality of HCC in the
nation. An analysis of the SEER national database found a 70% increase in the
incidence rate rising from 1.4 per 100,000 for the period 1976-1980 to 2.4 per 100,000
for the period 1991-1995 with a more pronounced increase among black males
compared to white men18.
The mortality rates followed a similar trend with a 41% increase from 1981 to
199518. Over the last four decades, mortality rates from HCC doubled for the total
population and males, while they increased by 50% for females. From 1969 to 2009,
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there was a disparity by unemployment with increased mortality associated with higher
unemployment levels15. The same disparity according to unemployment was present
after adjusting for age, race and sex.
The overall 1-year cause-specific survival rates almost doubled between 1992
and 2004, explained by an increase in the number of patients diagnosed with earlystage HCC which has an improved prognosis compared to late-stage HCC. American
Indians/Alaska Natives were the only racial and ethnic group who did not experience
this increase in survival rates9. Overall median survival increased significantly from the
1970s to 2000s rising from 2 months to 8 months19.
The prognosis of HCC depends on the etiologic factor, the genotype of HBV (if
this infection is present), as well as other underlying factors. More fully understanding
the risk factors for HCC and the factors determining better survival will improve the
management and treatment of HCC patients and may lead to interventions to reduce its
incidence and mortality and increase long-term survival and quality of life.
Overview of project processes
The data provided by the KRC is collected through the Cancer Patient Data
Management System which is a reporting system from all acute care hospitals,
outpatient facilities and health care facilities including treatment centers, private
laboratories and physician offices in the state of Kentucky. Since 2000, the KRC is also
part of the national SEER program, considered as the most accurate and complete
cancer registry in the U.S. County-level population data was retrieved from the Census
website and behavioral data was procured from the Kentucky BFRSS data. SAS 9.4®
and IBM SPSS 22® statistical softwares were used for all the analyses. Descriptive
4

statistics and regression modeling were used to describe the factors associated with
HCC occurrence and those which influence survival.
Scope and importance of the study
The knowledge of racial, socio-cultural, economic and lifestyle factors is
necessary to assess the occurrence and prognosis of HCC. Most studies on the risk
factors of HCC do not look specifically at the risk of later diagnosis nor at the
geographical difference. The present capstone will increase existing knowledge about
associations between various factors and risk of late-stage HCC in the Kentucky
population. It will also identify the factors associated with better survival, with a
particular emphasis on gender difference as well as menopausal status in female
cancer patients.
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II.

CHAPTER 2: LITERATURE REVIEW
Several risk factors for the occurrence of HCC have been identified, from viral

infections to environmental factors and lifestyle behaviors. El-Serag found a high
ecologic correlation between HCC and HBV chronic infection20. Chronic HBV infection is
the dominant risk factor of HCC in Africa and Asia, with the exception of Japan where
HCV chronic infection is the most frequent risk factor. Several factors have been
associated with an increased risk of HCC among HBV carriers: male sex, older age,
Asian or African ancestry, family history of HCC, higher levels of HBV replication HBV
genotype, longer duration of infection, co-infection with HCV, human immunodeficiency
virus [HIV], or hepatitis D virus, cirrhosis, exposure to aflatoxin, and heavy intake of
alcohol or tobacco20,21. HCV infection is also associated with an increased risk of HCC.
Risk factors among HCV carriers include any level of HCV viremia, genotype 1b, male
sex, alcohol22,23. Although the mechanism is unknown, coffee consumption seems to
have a protective effect against HCC in HCV carriers20,24. HBV and HCV are likely to
remain the main risk factors for HCC. It is thus important to maintain surveillance as to
identify the high risk groups and target early detection and treatment.
Role of HBV genomics in the risk of HCC

Because HBV is a major risk for HCC and it is a major public health problem, it is

important to investigate how HBV genotypes and its genomic variations and mutations
influence HCC carcinogenesis. Different HBV genotypes and sub-genotypes have been
studied to identify their association with the occurrence of HCC. The genotypes
associated with an increased risk of HCC are C2, F I a and J. Genomic mutations such
as PreS deletions, and precore mutations, particularly those in C1653T, T1753V, and
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A1762T/G1764A increase HCC risk 25. It is thus important to integrate the surveillance
of HBV mutations as well as genetic susceptibility in the classification of HBV patients in
order to determine those at higher HCC risk to provide antiviral treatment.
An updated meta-analysis of 85 case-control studies involved 16,745 HBVinfected patients, of whom 5781 had HCC. Precore mutation G1896A, G1899A and PreS mutation especially Pre-S1 and Pre-S2 deletion were correlated to an increased risk
of HCC. Similar correlation existed between basal core promoter (BCP) double mutation
A1762T/G1764A, T1753V, C1653T and HCC. Patients of Asian ethnicity, genotype C or
HBeAg positive were possibly more susceptible to HCC. Besides, the mutations like
G1896A and BCP double mutation may be associated with the progression of liver
diseases26.
Hwai-I Yang et al. aimed to examine the prevalence of HBV genotype and
precore and BCP mutants and their association with HCC risk after adjusting for wellknown host and viral risk factors27. This study took place in Taiwan in the framework of
the REVEAL-HBV cohort study, a community-based prospective cohort study which
investigated the association between viral factors and the risk of liver diseases. From
the cohort of 23,820 residents of seven towns free of HCC, 1,526 were tested for
precore1896 and BCP 1762/1764 mutations after excluding participants with negative
Hepatitis B surface antigen (HBsAg), antibodies against HCV infection, unknown antiHCV antibody status, undetectable baseline serum HBV DNA levels, or inadequate
blood sample for HBV genotyping and those with less than 10,000 copies or more of
HBV DNA per milliliter. The Cox regression model allowed identifying HBV genotype C
and specific alleles of BCP and precore mutants as risk factors of HCC 27. The
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prevalence of HCV genotype was constant in all age groups while the precore G1869A
and the BCP A1762T/G1764A double mutation increased with age. Participants with
genotype B had higher prevalence of the precore mutation while those with genotype C
had higher prevalence of BCP mutation and higher viral load. HCC incidence rates per
100,000 person-years were 305.6 and 785.8 for genotypes B and C, respectively.
Incidence rates were higher with the precore wild-type G1896 variant and the BCP
A1762T/G1764A double mutant. Genotype C was associated with a 2.35 times
increased risk of HCC while adjusting for sex, age, cigarette smoking, alcohol drinking,
serum ALT level, cirrhosis at study entry, HBV DNA level, and HBV genotype. The risk
was 1.76 times higher for genotype C after adjusting for sex, age, cigarette smoking,
alcohol drinking, serum ALT level, cirrhosis at study entry, HBV DNA level, HBV
genotype, and precore and BCP mutants. Genotype B and wild type for the precore
1896 and BCP 1762/1764 variants were associated with a decreased risk of HCC.
In another cohort study, chronic HBV patients in Hong Kong were prospectively
followed to determine the independent risk factor(s) for HCC development28. The
secondary aim was to investigate disease progression and effect on HCC development
among patients infected with different HBV genotypes. An overall incidence of 1,502
cases per 100,000 person-years was estimated for the total of 426 patients (65.3%
males) followed for a total of 1664 person-years. Age greater than 40 years, male sex,
presence of clinical liver cirrhosis, BCP mutations, and HBV genotype C were
associated with the development of HCC while HBeAg positivity and ALT levels were
not associated with HCC development. A Cox proportional hazard model identified
clinical liver cirrhosis and genotype C HBV infection as being independently associated
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with HCC development. Clinical liver cirrhosis was the strongest predictor of HCC
development with an adjusted relative risk of 10.24 (95% CI 4.39–23.89), whereas HBV
genotype C had an adjusted hazard ratio of 2.84 (95% CI 1.05–7.72). The incidence of
HCC development was respectively 1.1-fold and 2.3-fold higher in HBV genotype C
compared to genotype B, in patients with and without clinical cirrhosis28.
In a Taiwanese nested case-control study among participants of a large cohort of
male HBV carriers, the authors examined the sequence variation in the
EnhII/BCP/precore region of HBV using blood samples taken up to 14 years before
diagnosis29. This design was chosen to counteract the lack of information on the
temporal relation between nucleotide variations and HCC, the mutations possibly
occurring in the course of the infection. HCC cases were confirmed either by a
histological finding or elevated serum a-fetoprotein (>400 ng/ml) combined with at least
one positive image on angiography, sonography and/or computed tomography, from
August 1988 to December 2002. The matched controls were living members of the
HBsAg carriers’ cohort who had not been diagnosed with HCC throughout the follow-up
period. HBV genotype, BCP double variants, anti-HBe and ALT levels were significantly
associated with the risk of HCC. A significant positive association between the BCP
double variants (mostly T1762/A1764) and HCC was observed even after adjusting for
ALT levels and other viral factors, including genotype, viral load, HBeAg/anti-HBe
status, and other sequence variants29.
Gao et al. investigated the association between HBV preS mutations, with
particular interest in preS deletion mutations, and the clinical outcome among Chinese
patients with genotype C HBV infection30. The study included 79 HBV-infected patients-
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25 asymptomatic carriers (ASC), 28 chronic hepatitis B (CHB) patients, and 26 HCC
patients. The age and percentage of males significantly increased as disease severity
increased. CHB patients had significantly higher levels of Serum ALT and AST levels
while HCC patients had increased frequencies of preS deletion (38.46% versus 7.14%
and 4.00% in CHB and ASC patients, respectively. P = 0.001). The HBeAg-positive rate
and HBV DNA levels were comparable between patients with and without the preS
mutation. Although the precise mechanism for hepatocarcinogenesis in persistent HBV
infection is still imprecise, HBV genotypes may play some role in this process, and preS
mutations might account for a part of the genotype difference in the development of
HCC30.

Life style factors have been associated with the occurrence of HCC. Evaluating
whether these modifiable factors increase the risk of HCC is important in that it will allow
the planning of targeted interventions to reduce the burden of this deadly disease.
Overweight, obesity and the risk of HCC

Obesity (body mass index > 30kg/m2) is a risk factor for several diseases, from

cardiovascular to cancer. Liver cancer has the highest obesity-related excess risk31. The
excess risk for HCC in obese and overweight patients ranges from 17% to 89%, with an
average increase of 24% for each 5kg/m2 increase in BMI32. More than 36% of HCC
cases were attributed to obesity and diabetes in an American population-based case
control study (OR = 2.47, 95% CI = 2.34– 2.61) 33. The effect of obesity on HCC risk
was reviewed from thirteen studies (ten cohort studies, a nested case-control and two
case-control studies). A statistically significant increased risk of HCC with increasing
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BMI levels was reported by seven cohort studies (relative risk ranging from 1.4 to 4.1)
while one study reported a greater risk in white USA veterans and lower risk in black
veterans. The two other cohort studies did not find an association34.

In a dose-response meta-analysis of eight articles reporting twelve studies
compiling findings from 1,779, 471 individuals followed-up between 3.6 years and 19
years, Rui et al. found a significant increase of 1.02, 1.35 and 2.22-fold in the relative
risk for HCC incidence when BMI was at the point of 25, 30 and 35 kg/m2 compared
with reference (the median value of the lowest category), respectively. Given the
heterogeneity of the overall sample (mainly due to ethnicity), a stratified analysis was
performed and still showed the increased risk of HCC with increasing BMI 35.

In a Danish cohort of 285,884 individuals followed up more than 30 years for a
total of 6,963,105 person-years, a positive association between adult onset HCC and
BMI z-scores at each age from 7 to 13 years in boys and girls combined was found36.
The association was still present even after censoring patients with alcohol-related
disorders, viral hepatitis, and biliary cirrhosis. The increased risk for liver cancer in
adulthood was 19% and 36% higher, the HR of liver cancer per unit increase in BMI zscore at 7 and 13 years of age, respectively [HR (95% CI): 1.19 (1.04–1.38) and 1.36
(1.17–1.58)].
Metabolic disorders and HCC risk

Obesity constitutes a risk factor for diabetes mellitus (DM) and the determination

of their independent and joint effects is important in the planning of HCC control
interventions. Polesel et al. investigated the association between obesity, DM and HCC
11

risk37. This Italian case control study included 185 HCC patients and 404 controls.
Obesity was associated with a two-fold increase in HCC risk (OR = 1.9, 95% CI 0.9–3.9)
while DM was associated with nearly 4-fold increased risk (OR = 3.7, 95% CI 1.7–8.4).
Furthermore, diabetic obese participants had a five-fold increased risk compared to
non-obese non-diabetic. Among HBV and HCV-negative subjects, obesity and DM were
both associated with a 3.5-fold increased HCC risk and the combination of these two
conditions was associated with a 10-fold increase in risk (OR = 11.8 for obese diabetics
compared to non-obese non-diabetic subjects) 37.

Obesity is often associated with type 2 diabetes (due to insulin resistance),
metabolic syndrome (MS), and nonalcoholic fatty liver disease (NAFLD). The U.S.
National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III),
defines MS as the presence of at least three of the following conditions: elevated waist
circumference/central obesity, dyslipidemia (elevated triglycerides, lowered high-density
lipoprotein), hypertension, and impaired fasting glucose 38. Welzel et al. investigated the
association between MS and risk of HCC and intrahepatic cholangiocarcinoma (ICC) in
the general population of the United States. Impaired fasting glucose and/or DM was
associated with 2.9- and 1.82-fold increased risks of HCC and ICC39. In addition,
dyslipoproteinemia, hypertension, and obesity were each significant predictor of both
HCC and ICC. Subjects with MS had a 2.58- and 2.04-fold higher risk of HCC and ICC,
respectively (95% CI = 2.4-2.76 [HCC] and 1.74-2.40 [ICC]. After adjusting for
demographic variables and major HCC or ICC risk factors, the increased risk associated
with MS was 2.13-fold for HCC (95% CI = 1.96-2.31) and 1.56-fold for ICC (95% CI =
1.32-1.83) 39.
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Smoking and HCC risk

Smoking is a known risk factor for several cancers, explained by the fact several

constituents of tobacco smoke are known carcinogens in animals as well as in humans
(N-nitrosodimethylamine, 4-aminobiphenyl, arsenic, vinyl chloride)40,39,41. Although
controversial, the role of smoking in the occurrence of liver cancer has been explored by
several studies. However, most of the early studies exploring this association did not
account for the potential confounding by other risk factors of liver cancer40,42.

A meta-analysis of 96 cohort and case control studies found a moderate 1.5-fold
increase in HCC risk for current smokers. Ever and current smoking had an increased
risk for HCC compared to never smoking with meta-relative risk (mRR) of 1.27 (1.02–
1.58) and 1.51 (1.37–1.67), respectively. For high quality studies (consideration of major
potential confounders and with appropriate control selections), the associations were
stronger and the mRR was significant for former smoking also [1.18 (1.01–1.39)]. A
dose-response was found with increased risk with increasing quantity of cigarette
smoked. Despite the heterogeneity of the data, the findings support the conclusion of
the International Agency for Research on Cancer (IARC) of the etiologic role of smoking
in the occurrence of HCC 43.

Koh et al. examined the independent effect of smoking on HCC risk without the
confounding effect of alcohol consumption in a case control study nested in a Singapore
Chinese cohort44. Confirmed HCC cases were included in the nested study with a ratio
of three controls for one case. Compared to never smokers, current smokers had an
increased risk of HCC after controlling for alcohol intake and others major confounders
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(HR = 1.63; 95% CI = 1.27–2.10). Furthermore, there was a significant dose-dependent
association between daily number of cigarettes smoked and the risk of HCC among
current smokers. In ever smokers, a significant dose response was found between HCC
and duration and pack-years of smoking. When the authors restricted the analysis to
participants negative for HBV and HBC who were not daily drinkers, ever smokers had
a 1.85-fold increased risk compared to never smokers 44.
Alcohol and risk of HCC

Alcohol-related liver disorders accounted for 23.5% of HCC cases occurring in

the United States between 1991 and 2007 (OR = 4.06, 95% CI = 3.82– 4.32) 33. Morgan
et al. examined the role of alcohol intake as primary cause or cofactor in the
development of HCC. Chronic and heavy alcohol consumption was associated with an
approximately 2-fold increased odds ratio for HCC. The odds ratio increases to 5- to 7fold when ethanol use exceeded 80 g/day for more than 10 years. In the presence of
HCV, HBV or diabetes, alcohol increased the risk of HCC by 2 to 5 – fold 45.

The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/
Cancer–Hepatitis B Virus (REVEAL–HBV) Study Cohort investigated the joint effect of
obesity and alcohol consumption on the risk of HCC46. The independent predictors
identified by the multivariable Cox regression model were: age, alcohol use, HBeAg
status, HBV-DNA levels, and cirrhosis at baseline. Increased but not significant hazard
ratios were found for BMI, smoking, increased alanine aminotransferase (ALT) levels,
and interaction between BMI and alcohol. Alcohol use was associated with a 54%
increased risk of HCC (HR = 1.54; 95% CI: 1.04 –2.29). A 3-fold increased risk was
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found among obese alcohol users compared to non-obese alcohol users (adjusted HR =
3.40; 95% CI, 1.24 –9.34). In addition, a trend was observed with increasing risk with
increasing BMI. Obese individuals who had 20 years or more of alcohol use had an 8fold increased risk compared to those with less than 20 years of alcohol use (HR = 8.2;
95% CI, 3.0 –23.0) 46.
Factors influencing HCC survival

HCC survival has been associated with female gender, early diagnosis, Child-

Turcotte-Pugh class A classification for severity of cirrhosis, tumor size ≤ 2cm, initial
complete response to percutaneous ablation, transplantation and resection of localizedstage tumors, screening, low serum bilirubin and alpha-fetoprotein (AFP) levels and low
tumor mass9,47–49.

The independent role of smoking in liver cancer survival has seldom been
researched and the study results are ambiguous. Pre-diagnosis smoking and alcohol
were inversely associated with HCC survival. Shih et al. found that cessation had a
positive effect on mortality, but only after a long period (≥10 years)50. Siegel et al. found
that younger age, lower AFP and Child-Turcotte-Pugh Class were all independently
predictive of survival, but smoking was not. Neither the intensity of smoking nor smoking
cessation were associated with an improved survival51.

The American Association of the Study of Liver Diseases recommends screening
for HCC by ultrasound every six months in at-risk patients with chronic HBV including
Asian females over 50 years old, Asian males over 40 years old, all cirrhotic patients,
and those with a family history of HCC 52. Sarkar et al. described the evolution of
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screening practice, the factors associated with it as well as its impact on patient survival
in an Asian American cohort 49. The predictors of screening were age 40–64 years,
female gender, the presence of cirrhosis, liver clinic attendance, recent HBV diagnosis,
and testing for HBeAg. High ALT was negatively associated with screening and high
HBV viral load was independently associated with screening among cirrhotic patients.
HCC survival was associated with low Model for End-Stage Liver Disease (MELD)
score and curative treatment. Mean survival was significantly higher in HCC patients
who had been screened, and thus were more likely to have an early diagnosis.

Treatment is an influential factor in the improvement of survival, and was
responsible of the dramatic change in the prognosis of HCC which was once
synonymous of a death sentence with a very short survival time. In a randomized
controlled trial, transarterial Lipiodol chemoembolization induced a prolonged survival in
Asian patients with unresectable HCC53. Among HCC patients with unresectable and
untransplantable tumors, patients over 55 years had an increased bilirubin and AFP
levels and a decreased survival. Patients with small tumors and low typical AFP levels
have longer survival compared to those with AFP levels close to 250 and relative tumor
mass of about 40 have a survival of about a year47. A randomized, double-blind,
placebo-controlled trial among naïve systemic treatment HCC patients with ChildTurcotte-Pugh class A assessed the efficacy and safety of Sorafenib (an oral
multikinase inhibitor with antiproliferative and antiangiogenic effects) in the Asia-Pacific
region 54. Patients randomized to Sorafenib had 68% longer median overall survival
compared to those assigned to placebo: 6.5 months versus 4.2 months (p=0.014). The
6-month overall survival was 53.3% in the Sorafenib group compared to 36.7% in the
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placebo group. The hazard ratio for the time to progression, defined as from the time
from randomization to disease progression or symptomatic progression, was 0.57 in
favor of the Sorafenib group (p=0.0005). This study by Cheng et al. was done after the
multicenter, phase 3, double-blind, placebo-controlled trial aiming to assess the
Sorafenib (at a dose of 400 mg twice daily) versus placebo52. Llovet et al. showed that
Sorafenib was efficacious and well-tolerated in patients with advanced hepatocellular
carcinoma. The Sorafenib group had three months’ median survival benefit compared to
the placebo group.

Gender differences in HCC survival have been shown in some studies. Dohmen
et al. found that survival was longer in female HCC patients. The 1-, 3-, 5- and 7-year
survivals were significantly higher in females: 73.5, 50.3, 26.3 and 15.4% versus males:
67.7, 40.6, 23.8 and 8.7% (P-value: 0.0167). However, age, tumor size, number of
tumors, portal thrombosis and types of follow-up were significantly different between
males and females indicating that the stage at diagnosis could explain the longer
survival in females48.

Hepatitis viral infections may have a role in HCC survival as they constitute the
etiology of most of the cases. A Russian study explored the influence of HBV and HVC
on the survival of HCC patients. HBV and HVC infection was present in 39.9% and
17.4% of HCC patients, respectively. Although the Kaplan-Meyer estimates showed a
two-fold 5-year survival for virus-free patients (22.4% for virus-free vs. 9.5% for HBV;
13.0% for HCV; 6.1% for HBV and HCV), in the adjusted model the survival was similar
except for a small group with HVB/HVC co-infection55.
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A California study found that Laotian/Hmong and Cambodian HCC patients had
respectively a twofold and 74% higher cause-specific mortality compared to other ethnic
groups. This disparity in survival remained after adjustment for time period of diagnosis,
age at diagnosis, gender, geographic region, stage at diagnosis, type of surgery, and
socio-economic status (49% and 77% higher mortality for Laotian/Hmong and
Cambodian, respectively)56. Black patients had a poorer survival compared to Hispanics
and whites HCC patients57.
Conclusion

Cancer of the liver and intrahepatic bile duct incidence and mortality were two- to

three-fold higher in men compared to women, in all the trend analyses performed by
SEER for the period 1975-2012. The overall delay-adjusted incidence rose from 2.64
per 100,000 in 1975 to 8.91 per 100,000 in the SEER 9 regions, with most of the
increase observed in males. The same trend was observed for the age-adjusted
mortality rates58.

HBV genotype C and genetic mutations such as precore mutations, pre S
deletions and BCP double mutations were associated with an increased HCC risk 25–30.
With the highest obesity-related excess risk28, HCC risk increases with increasing BMI
levels 33–35 with a 24% increase for each 5 kg/m2 increment in BMI31,32. Childhood
obesity accounted respectively for 19% and 36% higher HCC risk per unit increase in
BMI risk at age 7 and 13 years36.

When associated with other metabolic disorders (DM, MS, NAFLD), the role of
obesity in HCC is even more prominent with up to a 10-fold increase in obese
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diabetics37–39. Known carcinogen, smoking and its role have been investigated in the
occurrence of HCC yielding results sometimes controversial or incomplete40–42.
Smoking increases HCC risk with a positive dose-response, the risk higher when the
dose or duration of smoking is higher43,44. Alcohol use has been associated with a 2-fold
increased HCC risk. The risk is even higher in chronic and heavy alcohol use as well as
when associated with smoking, diabetes, obesity and hepatitis infections45,46.

The influence of socio-demographic and tumor-related factors as well as
treatment on HCC survival are well established, with better survival associated with
female gender, small tumors and curative treatments and younger age9,47–49,51–54.
Smoking and alcohol use are inversely associated with HC survival and the positive
effect of smoking cessation was seen after at least 10 years50. HCC risk factors and
survival studies in the United States have been more focused on special groups such as
immigrants or those with Asian ancestry56,57. The role of race and unemployment have
been explored15,16.

To date, there is no study which has explored Kentucky population, with its
regional characteristics and their potential influence on the risk factors and survival of
HCC.
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III.

CHAPTER 3: RISK FACTORS IN KENTUCKY FOR LATE-STAGE
HEPATOCELLULAR CARCINOMA (HCC)

Introduction
The literature review described male gender, HBV and HVC infections, HBV
genotypes and genomic mutations, obesity, alcohol consumption, diabetes and other
metabolic disorders among the usual risk factors associated with HCC. The individual
role of smoking has been established as well as its worsening factor when associated
with others known risk factors. In this chapter, the risk factors for late stage liver cancer
in incident HCC patients reported to the Kentucky Cancer Registry (KCR) are
investigated. Only potential risk factors available in the KCR or county-level variables
from the Behaviorial Risk Factor Surveillance System (BRFSS) are evaluated. HBV and
HVC infections were not available for study. Also, this evaluation only included HCC
cases and no individual data were available on the population from which the HCC
cases came, and no non-case population was available for comparison. Therefore, the
risk factors for developing HCC in Kentucky was not studied.
Since diagnosis of HCC in late-stage is associated with poorer prognosis and
lower survivability, the focus of this chapter (paper) is an evaluation of the risk factors
associated with being diagnosed with late-stage HCC in Kentucky. The initial
hypotheses tested were that black race; Appalachian residence; low, county-level
education level; county-level binge drinking proportions (defined as as four or more
drinks for women and five or more drinks for men on any occasion during the past 30
days); and single status conferred a higher risk of being diagnosed with late-stage liver
cancer.
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Methodology

Data source and study population
The data used for this project were provided by KCR. Voluntary when it began in
1986, KRC was established as a population-based central cancer registry for the
Commonwealth in 1990 and the reporting became requisite the following year. The
Cancer Patient Data Management System is used as a reporting system by all acute
care hospitals, outpatient facilities and health care facilities including treatment centers,
private laboratories and physician offices. KCR maintains active surveillance of case
status using linkages with state vital records and the National Death Index. The KCR
collects uniform, high quality cancer data on incident cancer cases among Kentucky
residents. Since 2000, KRC has been part of the national SEER program, considered
as the most accurate and complete cancer registry. KCR contributes to the integrated
cancer control effort led by the Markey Cancer Control Program and has received the
gold certification of the North American Association of Central Cancer Registries
(NAACCR) since 199959.
Sample
The inclusion criteria for the HCC patients in this study were:


Invasive liver cancer cases that occurred in Kentucky from 1995 to 2011.



First primary or only primary cancer.



Age ≥ 20 to exclude childhood liver cancers.

Since major hypotheses studied were that black race and single status conferred
higher risk for being diagnosed with HCC in late-stage, cases with missing and
erroneous values for race or marriage were excluded from the analysis.
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Lifestyle covariates (obesity, smoking, alcohol consumption, physical activity)
and socio-economic indicators (education, income, poverty) were retrieved from the
Behavioral Risk Factor Surveillance System (BFRSS) at the county level. These county
level variables were merged with the individual data from KRC.
Variable definition
The potential predictors and confounders were determined according to the
factors associated with HCC incidence found in the literature. The variables were
defined as follow:


Age: continuous variable, further categorized (1 = <50; 2 = 50-64; 3= 65-74;
4=≥75.



Sex: binary variable 1 = Male; 2 = Female.



Smoking status: this category includes all types of tobacco products including
the non-smoke ones. Categorized in smokers and non-smokers. The countylevel smoking variable giving the proportion of smoking proportion was not
used in the analysis.



Race: 1=white/other; 2 = black.



Primary payer: categorical by type of insurance (not insured, private
insurance, Medicaid, or Medicare).



Marital status: categorical (single (never married), married (including common
law), separated, and widowed). The observations with missing and unknown
values were not analyzed. A binary variable was created with married
(currently married) and single.



Year of diagnosis: categorical 1=1995-1999; 2= 2000-2004; 3=2005-2009 and
4=2010-2011.
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Appalachia status: county-level binary variable with values as determined by
the Appalachian region commission. 1=Non-Appalachian; 2 = Appalachian.



Obesity rate: county-level continuous variable reporting the percentage age of
obese in the county. Categorized in low (<25%), intermediate (25-29%) and
high (≥30%).



Metro status: binary variable with values determined using the Beale codes.
1= urban (Beale codes 1-3); 2 = rural (Beale codes 4-9).



Poverty: percentage of the population under poverty level. Categorized in low
(<15%), intermediate (15-29%) and high (≥20%)



County-level yearly income: Average yearly income. Categorized in <15,000,
15,000-19,999 and ≥ 20,000.



Vital status which takes the value 0=Alive (censored) and 1=dead.



Histology: HCC (histology code 8170) and non-HCC (cholangiocarcinoma,
mixed hepatocellular carcinoma and cholangiocarcinoma,
cystadenocarcinoma in intrahepatic biliary ducts, undifferentiated carcinoma,
epithelioid hemangioendothelioma, angiosarcoma, rhabdomyosarcoma)



Stage: early stage (Summary stage 1 or best stage IIB) and late stage
(Summary stage 2 to 5 or Best Stage IIc to IV)

Variables with more than 10% of missing value as well as erroneous values were
not considered in the analysis.
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Data analysis
The SAS 9.4 Software Package (Version 9.4; SAS Institute Inc, Cary, NC) was
used to analyze the data. A descriptive analysis was done using the proc freq
procedure.
Demographic features and preexisting medical conditions were compared using t
tests for continuous variables and chi-square or Fisher’s exact tests for categorical
variables. A logistic regression was performed to calculate odds ratios (OR) and 95%
confidence intervals (95% CI) in order to assess the potential risk factors of late stage at
diagnosis HCC. The model was first run with all covariates and then variables were
removed using backward elimination to find the model of best fit. Tests of statistical
significance and CIs are two-sided. A p value < 0.05 is considered statistically
significant.
Observations with missing values were not considered in the analyses.
Results
Table III.1 presents the characteristics of the 2,205 HCC cases reported to the
KCR between 1995 and 2011. They were predominantly male (72.1%), with a mean
age at diagnosis of 64.1 years, ranging from 20 to 102 years. About half the study
population were smokers (53.1%), while only 21.99% never smoked. The number of
pack-years ranged from 1 to 320 among smokers with a mean of 27.2 pack-years.
Cases were more likely to be male (72.1%), of white or other race (90.2%), aged
between 50 and 64 years (39.9%), married (41.1%), diagnosed between 2005 and 2009
(81.54%) with a late stage (41.9%) HCC (78.4%) and have Medicare (50.7%). They
lived mostly in urban (59.5%) non-Appalachian area (72.1%). Female cases were
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mostly post-menopausal (87.3%), with a mean number of live births of 2.7. More than
half the sample did not receive any type of treatment (55.3%) and surgery was the most
frequent type of treatment among those treated (50.4%).
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Table III.1 : Characteristics of Incident Hepatocellular Carcinoma (HCC) Patients
Reported to the Kentucky Cancer Registry – 1995-2011
Patient-Level Continuous Variables
# Patients
Age at diagnosis
2205
Survival Time

2205

Number of live births (women)
206
Pack-years smoking
901
Patient-Level Categorical Variables
# Patients
Age at Diagnosis (yrs)
2205
<50
50 - 64
65 – 74
≥ 75
Gender
Male
2205
Female
Race
2202
White/Other
Black
Smoking Status
2205
Non-smoker
Smoker
Unknown
Marital Status
2205
Single
Married
Unknown
Insurance
2205
Not insured
Private insurance
Medicaid
Medicare
Unknown
Metro Status
2205
Urban
Rural
Appalachian Status
2205
Non-Appalachian
Appalachian
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Mean (StdDev)
64.08 years
(12.87 years)
12.43 months
(21.82 months)
2.7 (2.6)
27.2 (33.5)

Range

Frequency

percentage

20-102
0 – 168
0-13
0 – 320

259
879
559
508

11.75
39.86
25.35
23.04

1589
616

72.06
27.94

1989
213

90.20
9.66

469
1132
604

21.27
51.34
27.39

751
907
547

34.06
41.13
24.81

124
548
221
1117
195

5.62
24.85
10.02
50.66
8.84

1312
893

59.50
40.50

1589
616

72.06
27.94

Year of Diagnosis
1995 – 1999
2000 – 2004
2005 – 2009
2010 – 2011
Stage at Diagnosis
Early Stage
Late Stage
Unknown
Survival Duration (yrs)
≤5
6 – 10
>10
Histological Type
HCC
Non-HCC
Type of Treatment
No treatment
Surgical treatment
Chemotherapy
Radiation therapy
Other
Menopausal Status at Diagnosis
Pre-menopausal
Post-menopausal
Unknown

2205
424
559
815
407

19.23
25.35
36.96
18.46

826
923
456

37.46
41.86
20.68

2110
77
18

95.69
3.49
0.82

1729
476

78.41
21.59

1224
480
411
62
28

55.51
21.77
18.64
2.81
1.27

58
400
158

12.66
87.34
25.65

2205

2205

2205

2205

616

The county-level data associated with the 2205 cases is presented in Table III.2.
At the county level, the average literacy percentage of the residents from the counties
from which the HCC cases came was 74.8% (sd: 9.7%). The average percentage of
binge drinking, heavy drinking, smoker and ever smoker proportions were respectively
10.1%, 3.4%, 27% and 46.6%. More than three quarters of the population had a health
plan (which included Medicare or Medicaid). The mean yearly income was $18,513.6 .
The median percentage of residents living under poverty level was 17.4%. Obesity and

27

overweight proportions were on average 27.5% and 64.9% respectively while the
average exercise proportion was 67.7%.

Table III.2: County-Level Characteristics of Incident Hepatocellular Carcinoma (HCC)
Patients Reported to the Kentucky Cancer Registry – 1995-2011 – Data from the
Behavioral Risk Factor Surveillance System (BRFSS)
Variable
% Ever smoke cigarettes
% Currently smoke cigarettes
% Binge drinking
% Heavy drinkers
% Overweight
% Obese
% Physically active
% Literate
% With health insurance
% Live in poverty
Household yearly income

Median Value (StdError)
46.47 (0.09)
27.13 (0.09)
10.48 (0.07)
3.19 (0.03)
64.17 (0.07)
27.31 (0.09)
69.61 (0.13)
79.0 (0.21)
88.11 (0.12)
15.4 (0.13)
$18,339 ($85.40)

Range
32.13 – 64.08
15.4 – 46.9
1.4 – 18.03
0.2 – 6.5
51.7 – 75.3
19.3 – 41.6
49.7 – 81.1
49.4 – 86.5
66.3 – 93.96
5.8 – 38.3
$9,716 – 25,374

Table III.3 shows bivariate analyses by stage at diagnosis (excluding unknown
stage) for selected variables. The county-level variables percentage of ever smokers,
current smokers, health insurance were not included in this analysis as the individual
corresponding variables are available. The percentage of binge drinking was preferred
to the heavy drinking that is less frequent and percentage of obese was used instead of
percentage of overweight because obesity has a higher increased risk of death60.
Male gender, older age , black race, lack of insurance, year of diagnosis before
2000 HCC histology were statistically significant. White/other male aged 50-64,
diagnosed between 2005 and 2009 with HCC were more likely to be seen with a late
stage. Marital status, residence (metro or appalachia), smoking, binge drinking, physical
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activity, obesity, literacy, poverty and yearly income were not associated with stage at
diagnosis.
Table III.3: Bivariate analysis of Liver Cancer Cases in Kentucky by Stage at Diagnosis,
1995-2011
Variable
N

Stage at diagnosis
Early stage Late stage
N=826
N=923

Sex

P value

0.02
Male
Female

1279
470

70.6
29.4

75.4
24.6

White/Other
Black

1564
184

91.3
8.7

87.9
12.1

20-49
50-64
65-74
75+

213
711
455
370

13.0
42.6
22.6
21.8

11.5
38.9
29.0
20.6

Single
Married

621
768

44.2
55.8

45.2
54.8

Race

0.02

Age

0.02

Marital status

0.7

Appalachian Status
Non-Appalachia
Appalachia
Metro Status
Rural
Urban
Insurance
Not Insured
Insured
Medicaid
Medicare
Year of diagnosis
1995-1999
2000-2004
2005-2009
2010-2011
Smoking Status
Non-Smoker
Smoker

0.1
1283
466

71.6
28. 5

75.0
25.0

675
1074

39.2
60.8

38.0
62.0

112
490
197
919

5.4
30.0
13.3
51.3

7.6
27.2
9.8
55.5

263
418
714
354

11.6
23.9
43.0
21.5

18.1
23.9
38. 9
19.1

395
1002

29.3
70.7

27.4
72.6

0.6

0.01

0.001

0.4
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Histology
Non-HCC
HCC
Binge drinking proportion
<10%
≥10%
Physical activity proportion
<65%
65-69.9%
≥70%
Obesity proportion
<25%
25-29%
≥30%
Literacy proportion
<80%
≥80%
Yearly household income
<15,000
15,000 -19,999
≥20,000
Poverty proportion
<15%
15-19%
≥20%

0.004
304
1445

14.7
85.3

19.8
80.2
0.08

824
925

49.3
50.7

45.2
54.8

474
435
840

28.1
24.3
47.6

26.2
25.4
48.4

0.7

0.25
385
1000
364

23.1
55.1
21.8

21.0
59.1
19.9
0.4

855
894

49.9
50.1

48.0
52.0
0.5

397
559
793

23.8
32.0
44.2

21. 7
32.0
46.4

860
484
405

47.7
27.6
24.7

50.5
27.7
21.8

0.3

The full model for the logistic regression evaluating the risk of late stage at
diagnosis is presented in table III.4. In addition to the variables in our hypotheses (race,
Appalachian residence, county-level education, county-level binge drinking, and marital
status), other variables were included, whether to account for potential confounding or
because they are known risk factors: age, gender, insurance status, smoking status,
county-level percentage of exercise, county-level yearly income, and year of diagnosis.
Compared to the uninsured, those with private insurance and Medicaid had
respectively 41% and 46% less risk of being diagnosed with late stage (p=0.03 and
p=0.02). Medicare was close to being signifcant with a p-value of 0.08, showing that
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having any healthcare plan was protective for not being diagnosed with late-stage HCC.
Of the orginal hypotheses evaluated, black race had an odds ratio of 1.32 for being latestage with a p-value of 0.18. County-level percentage of binge drinking is significantly
associated with late stage diagnosis. With each increase of 1%, the odds of being
diagnosed late increased by 1.1-fold (p=0.03).
There was no evidence that being single imparted an increased risk for being
diagnosed with late-stage HCC. Appalachian residence, smoking status and countylevel low education do not appear to have any effect on late stage diagnosis.
Patients from counties with high literacy level (≥ 80%), moderate physical activity
(65-70%), moderate and high obesity percentage have a non-statistically significant
higher risk of late-stage diagnosis.
A significant interaction was found in the univariate logistic regression between
gender and age as well as between alcohol and gender (data not shown). Male cases
from counties with high percentage of binge drinking had a 1.3-fold higher odds (95%
CI: 1.05 – 1-71) of being diagnosed with late stage HCC compared to female from
counties with low percentage of binge drinking. Male cases aged 65-74 have almost a
two-fold higher odds of being diagnosed with late-stage (OR: 1.99; 95% CI 1.4 – 2.84)
compared to females aged 20-49. Although the males have higher odds in the other age
groups, the differences were not statistically significant. The only significant interaction
terms in the logistic regression was between gender and age and were thus kept in the
final model. Compared to females aged 20-49, males aged 65 to 74 years old had a
significant two-fold higher risk of late-stage diagnosis. At any age, males had a higher
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risk of late-stage diagnosis. In both males and females, the risk of late-stage diagnosis
increased with increasing age.
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Table III.4: Logistic Regression for the Risk Factors of Late Stage at Diagnosis (Full Complete
Model), Kentucky Residents, 1995-2011

Variables
Race

OR
White/Other Ref
Black 1.32

95% CI

p

0.88 – 1.98

0.6

Age * Gender
20-49, Female
20-49, male
50-64, male
65-74, male
≥75, male
50-64, female
65-74, female
≥75, female
Appalachia residence
Non appalachia
Appalachia
Marital status
Single
Married
Insurance
Not insured
Insured
Medicaid
Medicare
Smoking
Smoker
Non-smoker
Physical activity
Low
Moderate
High

Ref
0.75
1.16
2.0
1.14
0.73
0.74
0.62

0.39 – 1.44
0.73 – 1.83
1.16 – 3.48
0.63 – 2.07
0.32 – 1.64
0.3 – 1.79
0.26 – 1.49

0.6
0.3
0.05
0.2
0.4
0.5
0.2

Ref
0.83

0.55 – 1.26

0.4

Ref
0.97

0.74 – 1.26

0.8

Ref
0.54
0.49
0.61

0.32 – 0.91
0.28 - 0.86
0.35 – 1.06

0.02
0.02
0.08

Ref
1.12

0.84 – 1.49

0.4

Ref
0.97
0.92

0.63 – 1.49
0.53 – 1.6

0.8
0.4

% Binge drinking

1.1

1.0 – 1.12

0.05

Low Ref
High 1.07

0.67 – 1.72

0.8

Low Ref
Moderate 1.3
High 1.23

0.96 – 1.82
0.78 – 1.95

0.2
0.4

Literacy

Obesity
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The covariates retained in the final fitted model (see table III.5) after a backward
elimination of non-significant variables are the gender-age categories, insurance status,
race, year of diagnosis and county level % binge drinking. Although Appalachian
residence, county-level education and marital status were part of our initial hypotheses,
we chose to exclude them because they had high p-values and decreased the
goodness of fit.
Compared to females aged 20-49, the odds of late stage diagnosis in males
increased by 1.2-fold, 1.9-fold and 1.3-fold in ages 50-64, 64-74 and ≥75 respectively.
Compared to males, females had a decreased risk of 20% although the difference was
not significant.
The ininsured patients had an increased odds of 1.6-fold compared to those with
private insurance while Medicaid patients had a non significant decreased odd of 0.8fold and Medicare patients are not statistically different from the referent group.
Blacks had an increased odd of 1.5-fold compared to the white/other group. The
period 1995-1999 has a 1.8-fold increased odds of late diagnosis compared to the years
2010-2011 while the increased odds were not significant for the periods 2000-2004 and
2005-2009.
the county-level proportion of binge drinking was significantly associated with a
higher risk. Each 1% increase was associated with a 1.03-fold increased odds of late
diagnosis.
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Table III.4: Final model for the OR of late stage at diagnosis among Kentucky liver
cancer patients, 1995-2011
Covariates
Age*Gender
20-49, Female
20-49, male
50-64, male
65-74, male
≥75, male
50-64, female
65-74, female
≥75, female
Race
White/Other
Black
Insurance
Insured
Medicaid
Medicare
Not insured
Year of diagnosis
1995-1999
2000-2004
2005-2009
2010-2011
%Binge drinking
*Statistically significant

Late-stage
OR (95%CI)

P value
0.07

Referent
0.8 (0.4 – 1.5)
1.2 (0.8 – 1.7)
1.9 (1.2 – 3.0)
1.3 (0.8 – 2.03)
0.8 (0.4 – 1.6)
0.8 (0.4 – 1.5)
0.8 (0.4 – 1.5)
Referent
1.48 (1.0 – 2.1)*
Referent
0.8 (0.59 – 1.56)
1.1 (0.83 – 1.46)
1.6 (1.1 – 2.5)*
1.8 (1.27 – 2.5)*
1.2 (0.86 – 1.55)
1.04 (0.80 – 1.35)
Referent
1.04 (1.03 – 1.1)
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0.6
0.4
0.02
0.2
0.5
0.5
0.3
0.02
0.01
0.05
0.3
0.5
0.03
0.003
0.0009
0.3
0.8
0.03

Discussion

This study was conducted in a rural state with high poverty rates, high overweight

and obesity rates, low physical activity as well as low education level. The demographic
characteristics of Kentucky HCC patients are similar to HCC patients profile in the
country. Consistent with national reports9,61, our sample was mostly male, of white or
other race ethnicity and aged 50-64 years.
We did not find evidence that physical activity, marital status, literacy proportion
and Appalachia residence were associated with late-stage diagnosis of HCC. However,
our analysis confirms previous findings that gender, race, age, and insurance status as
factors impacting late-stage diagnosis15,33,62–65. Patients residing in counties with higher
levels of binge dirinking had a higher risk of late-stage diagnosis. We also found a
decreasing trend over time in the odds of HCC cases with late-stage diagnoses, with
diagnosis before 2000 having almost twice the risk of being late-stage. Thus, the
population with highest late stage HCC risk in this Kentucky sample are the blacks,
uninsured males aged 50 and older, living in counties with high proportion of binge
drinking and diagnosed before the year 2000.
Similar to national trends, HCC cases steadily increased between 1995 and 2009
with a higher proportion of the HCC cases being diagnosed with late-stage between
1995 and 199918,19. This trend may be due to an update in the management of HCC
with a better compliance to screening recommendation as well as the increasing age of
the population47,66.
Without surprise, our cancer cases were mostly males with a similar mean age at
diagnosis of 64 years as their national counterparts10. The male to female ratio of 2:1
supports the global trend of HCC incidence according to gender, with an increasing risk
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with increasing age. Access to care is highly correlated to the existence of insurance
plans and thus it is plausible that patients without insurance status have a higher risk of
late diagnosis as confirmed by previous research9,19,67,68.
Late-stage HCC diagnosis may be caused or worsened by diagnostic delays. A
Texan study found that almost 20% of HCC patients experienced delayed diagnostic of
more than three months, which can lead to an increase in tumor size 69. HCC is a highly
lethal disease making surveillance a primordial part of its management. Results from
the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial (HALT-C) suggest
that despite consistent surveillance, a third of patients are diagnosed with late-stage
HCC 70. This situation calls for an increase in provider awaressness to improve
surveillance and thus reduce the incidence of late-stage HCC.
Our analysis did not show our initial hypotheses that Appalachian residence, low
county-level education or single status provided a higher risk of late-stage HCC
diagnosis. County level literacy and poverty proportions, and average income were
used to assess socioeconomic level and were not associated with late-stage HCC.
Similar to our findings, a Canadian retrospective cohort exploring the risk factors of
HCC in the Ontario Cancer Registry data did not observe any association between
stage at diagnosis and SES 71. Ford et al., however, found that increased HCC rates in
New York city were associated with neighborhoods highly infected with HBV and HCV,
poorer, and inhabited by a high proportion of uninsured persons 72.
This study has several limitations. We lacked individual values for alcohol use,
education level, overweigh, obesity and physical activity. These variables would have
been more associated with personal risk if they were not simply at the county level. The
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lack of racial diversity of our series may impede the generalization of our findings.
Furthermore, our sample did not include information on HBV and HCV status, which are
known HCC risk factors. The missing values in some of our covariates of interest was
important. Stage of diagnosis, smoking status at diagnosis and marital status were
unkown in 20%, 27% and 25% of the sample, respectively. The observations with
unkown values were excluded from the logistic regression, which could have
contributed to the non significant findings for these variables.
Despite these limitations, this study is the first to our knowlegde exploring the risk
factors of late-stage HCC diagnosis in Kentucky. With the increasing incidence of HCC
in Kentucky, our findings suggest that the State’s efforts toward the control of HCC
should focus on implementing recommendations directed to uninsured males residents
aged 50 to 64 years. Moreover, further investigation is warranted to document the effect
of lifestyle (physical activity, smoking, alcohol use) on the risk of late stage HCC. With
evidence of a geographic variation in the epidemiology of HCC, it is paramount to study
the effect of socioeconomic status on the incidence of late-stage HCC for better tailored
interventions.
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IV.

CHAPTER 4: FACTORS ASSOCIATED WITH HCC SURVIVAL IN KENTUCKY

Introduction
Factors associated with increased HCC survival include female gender, early
diagnosis, a class A Child-Turcotte-Pugh cirrhosis score, tumor size ≤ 2cm, initial
complete response to percutaneous ablation, transplantation and resection of localizedstage tumors, screening, low serum bilirubin and alpha-fetoprotein (AFP) levels and low
tumor mass 9,47–52. The present study evaluates factors associated with longer survival
among Kentucky HCC patients who were diagnosed between 1995 and 2011 and
entered into the KCR. We examined both overall and specific survival with respect to
hormonal status, which has been found to be predictive of liver cancer incidence in
women. Furthermore, studies have shown that women have longer survival than men.
Our research hypothesis is that early stage diagnosis, female gender and nonsmoking status will be associated with a better HCC survival.
Methods

Data source and study population
Sample
The same data set described in chapter 3 was used for this part of the project.
Cases extracted from death certificate or autopsy only were excluded.
Variable definitions
In addition to those described in chapter 3, we considered the following variables:


Vital status which takes the value 0=alive (censored) and 1=dead.



Year of survival: continuous, used to compute the survival time in years. It
was categorized in three categories: ≤ 5 years, 6-10 years and >10 years.
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Histologic type: HCC and non-HCC.



Live births: number of live births at diagnosis. Categorized in 1=0; 2=1-2 and
3=>2.



Hormonal status: modified gender variable with 3 categories: men,
postmenopausal women and premenopausal women.

Data analysis
The primary end point is the overall survival and thus the outcome variable is the
time to event, a continuous variable calculated in days, computed by subtracting the
date of diagnosis from the date of death or last contact. Follow-up time for those still
alive at the time of the linkage with the National Death Index was calculated using the
date of diagnosis and date of last follow-up.
A descriptive analysis by hormonal status was performed in order to select the
variables that will be included in the survival analysis. A cross-tabulation of all the
variables of interest with overall and specific mortality was also performed for the
selection of the variables to be included in the Cox regression.
The 5-, 10- and 15-years survival rates were estimated using the Proc Lifetest
procedure. Both actuarial and Kaplan-Meyer methods were used. The mean overall
survival was calculated by hormonal status to assess whether the overall survival is
different across groups. A Cox proportional hazard model was fitted to determine the
effect of gender with both overall and specific survival. A subset of the data comprised
of female patients with available information on live births was used to further assess
the effect of menopausal status on both type of survival, adjusting for parity.
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The final survival model was selected using a backward elimination procedure.
The full complete model included all the independent variables and the interactions, as
reported in the literature or identified during the bivariate analysis. A two-way interaction
between treatment and stage at diagnosis was evaluated given that stage at diagnosis
determines the type of treatment available to patients.
Results

Table IV.1 presents the characteristics of the sample by hormonal status. This

bivariate analysis shows age, race, insurance status, smoking status, treatment,
metropolitan status, histological type, stage, marital status, and survival were
associated with hormonal status. County-level poverty, physical activity, binge drinking,
literacy proportions were significantly associated to hormonal status as well. Both
overall and specific mean survival were similar (9.8 %) in men and post menopausal
women and were significantly higher in premenopausal women (24.1 %).
Both overall and liver cancer specific survival rates were low. The 5-years overall
survival rates were 10.3%, 8.3% and 26% in men, post and pre-menaupausal women,
respectivelely while the 5-years specific survival rates were 19.3%, 19.3% and 30.3%
(data not shown). Mean overall survival for the study period was 9.8 % in men and
11.4% in females while mean specific survival was 29.5 % and 30.7 % and men and
women, respectively (data not shown).

Table IV.1: Stratified Analysis by Hormonal Status, Kentucky Residents, 1995-2011
Variables

#

%Men
N = 1589
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%Postmeno
pausal
women

%Premenop
ausal
women

P

N = 400

N = 58

Age

<.0001
<50
50-64
65-74
≥75

244
828
512
463

81.2
85.4
74.4
65.4

3.7
12.1
25.6
34.6

15.2
2.5
0
0

Race

0.04
Black
White/Other

196
1850

79.6
77.4

15.3
20.0

5.1
2.6

No treatment
Surgical treatment
Chemotherapy
Radiation therapy
Other
Appalachian Status
Non-Appalachia
Appalachia
Metro Status
Urban
Rural
Smoking Status
Non-Smoker
Smoker
Insurance
Not insured
Insured
Medicaid
Medicare
Stage at Diagnosis
Early Stage
Late Stage

1125
447
389
59
27

78.4
72.5
80.7
78.0
85.2

19.8
22.6
15.2
22.0
14.8

1.8
4.9
4.1
0
0

Treatment

0.002

0.11
1439
578

78.8
74.6

18.5
22.2

2.7
3.3
0.02

1215
832

79.7
74.6

17.5
22.6

2.9
2.8

443
1083

56.4
83.8

39.1
13.3

4.5
2.9

<.0001

<.0001
116
515
206
1052

88.0
79.6
84.5
72.5

6.0
14.4
9.2
27

6.0
6.0
6.3
0.5

774
872

75.3
79.8

21.5
17.3

3.2
2.9

1625
422

80.3
67.5

16.9
29.6

2.8
2.8

0.08

Histological Type

<.0001

HCC
Non-HCC
Marital Status at Diagnosis
Single (never married)
Married
Separated/ Divorced
Widowed
Mortality rates

≤5 years
6 – 10 years
>10 years

<.0001
225
857
262
203

89.3
83.1
80.2
44.3

6.2
14.2
16.0
55.7

4.4
2.8
3.1
0

1961
69
17

78.0
71.0
58.8

19.4
20.3
29.4

2.6
8.7
11.8

0.0033*
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Mean overall survival$ (%)

208

9.8

9.8

24.1

0.0005**

Mean specific survival$ (%)

611

29.5

30.5

34.5

0.03**

Year diagnosed

0.04
1995-1999
2000-2004
2005-2009
2010-2011

388
523
755
381

74.5
74.2
79.2
82.4

21.9
22.8
18.5
14.7

3.6
3.1
2.3
2.9

County-level %Literacy

0.5

Low
1053
76.5
20.6
Moderate
994
78.8
18.4
County-level yearly income
<15,000
490
74.1
23.3
15,000 – 20,000
677
77.4
19.4
≥ 20,000
880
79.8
17.2
County-level %Binge drinking
<10%
985
76.4
20.9
≥ 10%
1062
78.1
18.3
County-level %physical exercise
<70%
1109
75.5
21.6
≥ 70%
938
80.2
17.1
County-level %obesity
<30%
1610
78.1
19.1
≥ 30%
437
75.7
21.1
County-level % under poverty
<20%
1544
78.9
18.2
≥ 20%
503
73.8
23.7
$
*Chi-square may be invalid **Log-Rank Survival analysis, life table method
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2.9
2.8
0.1
2.7
2.7
3.1
0.3
2.7
2.9
0.03
2.9
2.8
0.6
2.7
3.2
0.03
2.9
2.6

Table IV.2 shows the unadjusted overall and specific survival rates for the
covariates selected after the bivariate analysis. The covariates associated with overall
survival were hormonal status, age at diagnosis, marital status, insurance status, year
of diagnosis, smoking, stage at diagnosis, treatment, histology and county-level proverty
proportion.
Unadjusted survival rates were significantly higer in premenopausal women,
women with children, younger patients (<65 years), married patients, those insured,
those diagnosed in 2010-2011. As expected, non-smokers, patients with early stage
HCC, those having had a surgical treatment had higher survival rates. Cases from and
with a poverty proportion < 20% had also higher survival rates. Year of diagnosis was
significantly associated with survival. Survival rates increased from 2.12% in 1995-1999
to 23.6% in 2010-2011.
Married cancer patients had longer survival compared to single. Survival rates
were shorter in smokers, in those diagnosed late, in those diagnosed between 1995 and
2004, with an almost two-fold increase in survival after 2005 and in non-HCC
histological cancer.
Survival was significantly different according to insurance status, with privately
insured having the highest survival and Medicare the lowest. Surgical treatment has the
highest survival rates while those who didn’t receive any treatment and those treated
with radiation have similar, much lower survival rates. Poverty proportion was
associated with overall survival but not with specific survial.
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Gender, race and metro/rural residence were not different in survival. Likewise,
our analysis did not find any association between both overall and specific survivals and
county level physical activity proportion.
Mean overall survival rates were 12.88%, 17.24 % and 24.14 % in men, post and
pre-menopausal women, respectively. The mean specific survival probabilities were
higher and the same trend is seen, with pre-menopausal women having a longer
survival than post-menopausal women and men (p-value for log-rank = 0.02).
The adjusted Kaplan-Meyer survival curves were significantly different according
to hormonal status, with pre-menopausal women having a better survival compared to
both men and postmenaupausal women (figure IV.1 and IV.2). Furthermore,
premenopausal women had better overall and cause-specific survival than their
postmenopausal counterparts (figures IV.3 and IV.4).
Both men and post-menopausal women have similar survival rates that are
significantly lower than pre-menopausal women. Of the 551 women with live births data,
3.99% without any live births have the same rate (4.55%) whether overall or specific
survival is considered. Survival rates increased with increasing number of live births, the
increase being more pronounced in specific survival. Unsurprisingly, increasing age is
associated with decreasing survival.
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Table IV.2: Unadjusted Overall and Specific Survival Rates by Covariate, Kentucky
Residents, 1995-2011
Covariates

Overall
survival rate

Gender
Male
Female

9.75
11.36

Hormonal status
Men
Post-menopausal women
Pre-menopausal women
Live births
0
1-2
>2
Race
Black
White/Other
Age at diagnosis
20-49
50-64
65-75
≥75
Marital status
Single
Married
Insurance status
Not insured
Insured
Medicaid
Medicare
Smoking status
Non-smoker
smoker
Residence
Rural
urban
Year of diagnosis
1995-1999
2000-2004
2005-2009
2010-2011
State at diagnosis
Early stage
Late stage

Log-rank
p value
0.09

Specific
survival rate
29.52
30.68

0.0005
9.75
9.75
24.14

0.02
29.52
30.5
34.48

0.01
4.55
12.5
12.27

0.0005
4.55
25
31.7

0.25
9.39
10.26

0.38
29.11
29.86

<0.0001
16.22
14.33
7.51
2.95

<0.0001
36.29
35.61
25.40
21.46

0.0004
9.85
14.44

0.006
31.82
34.84

<0.0001
16.13
18.43
12.67
6.62

<0.0001
42.74
36.50
38.91
27.04

0.02
12.37
9.54

0.01
33.9
29.15

0.05
8.40
11.43
2.12
5.55
10.92
23.59

0.15
28.67
30.64

<0.0001

13.92
28.26
32.27
43.73

<0.0001
20.22
4.55
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Log-rank p
value
0.2

<0.0001

<0.0001
47.70
21.02

Histology

<0.0001
HCC
Non-HCC

11.28
6.3

No treatment
Chemotherapy
Radiation therapy
Surgery
other
Poverty proportion
Low to intermediate
High
Physical activity
Low to moderate
high

1.80
7.54
1.61
35.42
3.57

Treatment

<0.0001
31.98
22.06

<.0001

<0.0001
18.06
27.25
27.42
62.08
35.71

0.04
11.4
6.94

0.18
30.32
28.33

0.07
9.06
11.55
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0.29
29.45
30.31

Figure IV-1: Kaplan Meier Curve for All-Cause Survival by Hormonal Status at
Diagnosis, Adjusted for Age, Stage and Treatment in Kentucky Residents, 1995-2011

Figure IV-2: Kaplan Meier Curve for Specific Survival by Hormonal Status at Diagnosis
in Kentucky Residents, Adjusted for Age, Smoking, Year Diagnosed, Treatment,
County-level % Binge Drinking, 1995-2011
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Figure IV-3: Kaplan Meier Curve for All-Cause Survival by Menopausal Status at
Diagnosis, Adjusted for Age, Stage and Treatment in Female Kentucky Residents,
1995-2011

Figure IV-4: Kaplan Meier Curve for Specific Survival by Menopausal Status at
Diagnosis in Female Kentucky Residents, Adjusted for Age, Smoking, Year Diagnosed,
Treatment, County-level % Binge Drinking, 1995-2011
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Men and post-menopausal women had a 1.75-fold and 1.7-fold higher hazard of
dying no matter the cause, compared to pre-menopausal women (Table IV.3). In
unadjusted specific survival, men and post-menopausal women had a significant 1.5fold increased risk of cause-specific mortality, compared to pre-menopausal women.
Table IV.3: Adjusted and Unadjusted Hazards Ratios for Overall and Cause Specific
Mortality among Kentucky Cancer Cases, 1995-2011
Unadjusted HR
& (95% CI)
All-cause survival

Adjusted HR
& (95% CI)

Men

1.75 (1.3 – 2.36); p=0.0003

1.38 (0.98 – 1.96)*

Post-menopausal women

1.70 (1.24 – 2.32); p=0.0009

1.38 (0.96 – 2.0)*

Liver-cancer specific survival
Men

1.5 (1.1 – 2.1); p=0.01

1.63 (0.78 – 1.74)#

Post-menopausal women

1.45 (1.03 – 2.04); p=0.03

1.19 (0.78 – 1.83)#

*Adjusting for age, treatment, stage, and two-way interaction between treatment and stage
#Adjusting for age, smoking, year diagnosed, treatment, stage, and two-way interaction between
treatment and stage

The full complete model for the Cox regression included all the covariates that
were found statistically significant in the overall and specific survival analysis by
covariate (see Table IV.2).
In the final adjusted model, the covariates that were predictive of a better overall
survival were being a premenopausal woman, diagnosed at an early stage and having
been treated. Both men and post-menaupausal women had a 1.38-fold increase in the
risk of dying no matter the cause compared to pre-menopausal women. Compared to
those diagnosed early, late stage cancer patients had an average 1.5-fold increase in
the risk of dying from all causes with radiation patients having the higest increase (2.2fold). As expected, patients without any treatment had the highest risk of death, with a
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5.3-fold and 4.9-fold increased risk of all cause death, for early and late stages,
respectively when compared to their counterparts who had surgery. In early stages, the
risk of death increased 3.1-fold, 2.9-fold, 2.8-fold in other treatment, radiation and
chemotherapy , respectively compared to surgery. In late stage, the risk of death
increased 3.3-fold, 2.7-fold and 2.2-fold in radiation therapy, other treatment and
chemotherapy compared to surgery. Although the hazard of dying increased with
increasing age, the difference was not significant.
Table IV.4: Adjusted Hazard Ratios for Liver Cancer-Overall Survival in Kentucky
Residents, N=1646, 1995-2011 (Fitted, Reduced Model)
Parameter

Hazard
Ratio

95% Hazard
Ratio Confidence
Limits

Hormonal status

P value

0.16
Pre-menopausal women
Men
Post-menopausal women

Referent
1.38
1.38

0.98 – 1.96
0.96 – 2.0

0.06
0.08
0.09

20-49
50-64
65-74
≥75

Referent
1.04
1.18
1.19

0.87 – 1.25
0.97 – 1.43
0.98 – 1.46

0.6
0.09
0.08
<.0001

Early stage
Late stage, chemotherapy
Late stage, no treament
Late stage, other
Late stage, radiation therapy
Late stage, surgery

Referent
1.45
1.76
1.64
2.20
1.90

Age

Stage at diagnosis
1.15 – 1.82
1.52 – 2.04
0.67 – 4.06
1.15 – 2.20
1.47 – 2.47

Treatment

<0.0001
Surgical treatment
Chemotherapy, early stage
No treatment, early stage
Other, early stage
Radiation therapy, early stage
Chemotherapy, late stage
No treatment, late stage
Other, late stage
Radiation therapy, late stage
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Referent
2.88
5.30
3.14
2.91
2.19
4.89
2.72
3.36

2.25 – 3.68
4.37 – 6.42
1.66 – 5.96
1.62 – 5.24
1.69 – 2.83
3.84 – 6.24
1.36 – 5.43
2.29 – 4.93

Specific survival was associated with smoking status, year diagnosed, treatment
and stage (Table IV.5). Smokers had a 1.2-fold increased risk compared to nonsmokers after adjusting for hormonal status, age at diagnosis, year diagnosed,
treatment and stage at diagnosis. Compared to those diagnosed in 2010-2011, patients
diagnosed in 1995-1999 and 2004-2009 had both a 1.3-fold increased risk of liver
cancer specific death, after adjusting for age, hormonal status, smoking, treatment and
stage while those diagnosed in 2000-2004 were not different from the referent group.
Compared to surgical treatment, those without any treatment had an average 6fold increased liver cancer specifc risk of death in early and late stages, respectively
after adjusting for age, hormonal status, smoking, year diagnosed and stage. In early
stage, the specific risk of death increased from other treatment to radiation and
chemotherapy while the increase rose from chemotherapy to other treatment, and
radiation therapy in late stage.
Compared to the early diagnosis, late stage liver cancer cases have a risk of
death that increases from those with chemotherapy (1.6-fold) to no treatment (1.9-fold),
surgery (2-fold), other treatment (2.3-fold) and radiation (2.9-fold).
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Table IV.5: Adjusted Hazard Ratios for Liver Cancer -Specific Survival for Kentucky
Residents, N=1333, 1995-2011 (Fitted, Reduced Model)
Parameter

Hormonal status
Pre-menopausal women
Men
Post-menopausal women
Age at diagnosis
20-49
50-64
65-74
≥75
Smoking
Non-smoker
Smoker
Year diagnosed
1995-1999
2000-2004
2005-2009
2010-2011
Treatment
Surgical treatment
Chemotherapy, early stage
No treatment, early stage
Other, early stage
Radiation therapy, early stage
Chemotherapy, late stage
No treatment, late stage
Other, late stage
Radiation therapy, late stage
Stage at diagnosis
Early stage
Late stage, chemotherapy
Late stage, no treament
Late stage, other
Late stage, radiation therapy
Late stage, surgery

Hazard
Ratio

95% Hazard Ratio
Confidence
Limits

P value

0.70
Referent
1.12
1.20

0.78 – 1.74
0.78– 1.83

0.46
0.66
0.43

Referent
0.98
1.13
1.07

0.78 – 1.24
0.86 – 1.43
0.83 – 1.38

0.88
0.33
0.60
0.059

Referent
1.2

1.0 – 1.4

1.32
1.02
1.25
Referent

1.05 – 1.65
0.83 – 1.27
1.03 – 1.51

0.01
0.02
0.84
0.03
<0.0001

Referent
3.36
6.47
2.51
2.81
2.54
5.88
2.75
3.84

2.38 – 4.73
4.90 – 8.54
0.79 – 8.03
1.29 – 6.12
1.82 – 3.56
4.25 – 8.12
1.16 – 6.53
2.33 – 6.34
<0.0001

referent
1.60
1.93
2.32
2.90
2.12

1.19 – 2.16
1.60 – 2.32
0.58 – 9.35
1.24 –6.76
1.47 – 3.06
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To consider the role of childbearing on the effect of menopausal status in liver
cancer survival, we performed a proportional hazard Cox regression on a sub-sample of
women with available childbearing data. Table IV.7 presents the hazards ratios
generated for both overall and specific survival.
Postmenopausal women had a non significant 2.2-fold increase in the risk of allcause death compared to premenopausal women, after adjusting for the number of live
births age at diagnosis, stage, treatment received and county-level % of physical
activity. The specific liver cancer risk of death is increased by 30% in postmenopausal
women compared to their premenopausal counterparts, after adjusting for childbearing,
age, stage, treatment and county-level physical exercise. These differences were not
statistically significant.
The adjusted risk of all-cause mortality and liver cancer specific mortality
decreased with increasing number of live births although the difference was not
significant. Compared to childless women, the adjusted risk of all-cause death
increased by 80% and 50% in women with 1-2 live births and ≥2 live births, respectively
while the risk of liver cancer mortality decreased by 10% in women with more than two
live births.
Age at diagnosis is associated with both all-cause and liver cancer specific
mortality, which increased with increasing age, with hazard ratios close to the
significance level. Early-stage at diagnosis, surgical type of treatment, residence in
county with ≥70% of people exercising were predictive of better survival. Late-stage
diagnosis increased by 70% the risk of all-cause death, compared to early stage, after
adjusting for age, menopausal status, childbearing, treatment and county level % of
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exercise. Compared to surgical treatment, patients whithout any treatment regimen had
an almost 5-fold increased risk of all-cause mortality, while radiation therapy and
chemotherapy had a 2.5-fold and 2-fold increase, respectively after adjusting for age,
menopausal status, childbearing, stage and county level % of exercise. Other treatment
was not significantly different from surgery for both all-cause and liver cancer mortality.
Liver cancer specific mortality is associated with late stage diagnosis (2.2-fold
increased mortality), treatment and county-level yearly income. The increased risk of
liver cancer mortality was respectiveley 6-fold, 3.5-fold and 3.2-fold in patients with no
treatment, radiation therapy and chemotherapy. Surprisingly, patient from county with
yearly household income ≥$20,000 had 60% more risk than their counterparts residing
in counties with yearly income <$15,000.
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Table IV.6: Hazard Ratios for Liver Cancer Survival in Kentucky Female Residents,
1995-2011
Covariates

Menopausal status
Pre-menopausal
Post-menopausal
Live births
0
1-2
>2
Age at diagnosis
20-49
50-64
65-74
≥75
Stage at diagnosis
Early stage
Late stage
Treatment
Surgical treatment
Chemotherapy
No treatment
Other
Radiation therapy
Physical activity
Low to moderate
High proportion
County-level
county-level yearly
income
<15,000
15,000-20,000
≥20,000

Overall survival N=409
Hazard
95% HR
P value
Ratio
CL
0.09
Referent
1
2.2
0.9 – 5.7
0.3
Referent
1.8
0.8 – 4.0
0.2
1.5
0.7 – 3.2
0.4
0.08
Referent
0.4
0.2 – 1.0
0.05
0.7
0.3 – 1.9
0.5
0.8
0.3 – 2.1
0.6
0.01
Referent
1.7
1.1 – 2.5
<0.0001
Referent
2.0
1.1 – 3.7
0.02
4.6
2.7 – 7.9
<.0001
0.9
0.1 – 7.5
1
2.5
1.0 – 6.1
0.05
0.005
Referent
1.7
1.2 – 2.5

Specific survival N=413
Hazard
95% HR
P value
Ratio
CL
0.7
Referent
1.3
0.4 – 3.7
0.9
Referent
1.0
0.4 – 2.4
1
0.9
0.4 – 2.2
0.9
0.07
Referent
0.4
0.1 - 1.2
0.2
0.9
0.3 – 3.0
0.8
0.9
0.3 – 2.9
0.9
0.001
Referent
2.2
1.4 – 3.4
<.0001
Referent
3.2
1.6 – 6.4
0.001
6.0
3.1 – 11.7
<.0001
1.4
0.2 – 11.4
0.9
3.5
1.3 – 9.6
0.005

0.04
Referent
0.8
1.6
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0.5 – 1.5
1.0 – 2.7

0.5
0.07

Discussion

Our main findings from this large population-based study which adjusted for age

and menopausal status in particular, show that early stage at diagnosis and treatment
are predictive of better overall survival while early stage at diagnosis, year of diagnosis,
non-smoking status and treatment regimen were predictors for a better specific survival.
Menopausal status and age were not significantly associated with survival.
However, our gender difference in all-cause and liver cancer specific survival, is close to
statistical significance, hinting to an effect of gender on survival, which is consistent with
the published literature. Indeed, an improved survival in female has been reported by
Dohmen et al.48 who hypothesied that the difference may be due to the lead-time bias.
Beal et al. have also reported increased mortality rates in males 73. A review by Cook
found a 17% increased risk in males compared to females, with a steadily increasing
male to female mortality rate ratio of 2.03, 2.18 and 2.33 for the periods 1977-1986,
1987-1996 and 1997-2006, respectively 74.
Our results show that premenopausal women had better five years survival than
both men and postmenopausal women, which corroborates the increased risk in males
found in other studies.
We found a 20% increased risk of cause-specific deaths in smokers, which has
also been reported by Siegel et al. and Shih et al. 50,51. However, the magnitude of the
difference they found is bigger (60% and 70% increased mortality) and may be
attributed to the fact they investigated the joint effect of smoking and drinking on liver
cancer survival. Evans et al. found that smoking was associated with a decreased
survival in female only 75. Jee et al. also found a 40% increased risk of death in current
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smokers compared to never smokers 11. The observed increased mortality in smokers
may be attributed to the presence of toxic metabolites from smoking able to increase
cancer aggressiveness or the presence of comorbidities that will prevent smokers from
benefiting from treatment.
Year of diagnosis was another predictor of survival. Patients diagnosed before
2000 and between 2005 and 2009 had 32% and 25% increased risk for cause-specific
mortality than those diagnosed after 2010. This decrease in the risk of death with time
has also been observed by Beal et al. in recent birth cohorts 73 as did Altekruse et al.
9,61.

As expected, early stage diagnosis and treatment were associated with an

improved survival rate. Patients diagnosed late and did not receive any treatment had
an increased risk of cause-specific death of 93% compared to those who were
diagnosed early and had surgery. Similar to our results, several authors have found an
improved survival in early stage patients, which is understandable given the wider
treatment range available to them 76–78. Surveillance allowed the detection of early
cases and increased by two-fold the receipt of curative treatment 76.
To our knowledge, this study is the first to investigate liver cancer mortality in
Kentucky. The major strength if this study is that the data was provided by KRC, which
is a reliable and complete source for cancer incidence and mortality data for the state.
The use of the Cox multivariable regression method allowed to control for risk factors as
well as possible confounders as well as deal with censoring and delayed entry, as
patients are included at the time of cancer diagnosis that is different for each participant.
Our study has several limitations however. Hepatitis virus infections (B, C),
screening practice, intensity or duration of smoking and alcohol consumption have been
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associated with survival but we have not been able to explore those variables in our
analysis. More than 20% of our study sample has an unknown smoking status; this
could have underestimated the hazard ratio associated with smoking. Our analysis used
county-level obesity proprotion and county-level variables for assessing socioeconomic
status. Furture use of individual-level variables may allow a clearer picture of the
predictors of HCC survival. Finally, Kentucky has a very homogenous ethnic distribution
which limits the generalization of this study to other populations.
Our findings confirm the role of smoking status, as well as stage at diagnosis,
year of diagnosis and treatment on the survival rates of liver cancer patients. The
impact of screening, gender differences and the conjoining role of smoking and drinking
(highly correlated) need to be further investigated.
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V.

CHAPTER 5: CONCLUSION
This capstone project aimed to identify and describe the risk factors of late-stage

HCC diagnosis in Kentucky residents between 1995 and 2011 as well as identify the
factors predicting better survival. Our findings can be used to increase HCC awareness
within both the public and health care providers given the increasing HCC incidence in
the state and its high lethality. These results can be used for planning of interventions to
better target the highest risk population. They offer also an orientation on future
research.

Summary of Findings

Our working hypothesis for the investigation on the risk factors of late-stage liver

cancer was that a higher risk of being diagnosed with late-stage liver cancer will be
seen with black race; Appalachian residence; low county-level education level; countylevel binge drinking and single status. Our analysis of the 2,205 liver cancer cases that
occurred between 1995 and 2011 and retrieved from KCR did not show that
Appalachian residence, low county-level education level and single status conferred a
higher risk of late-stage liver cancer diagnosis. Nevertheless, our analysis confirms
previous studies that race and county-level proportion of binge drinking (as continious
variable) increased the risk of late-stage diagnosis15,33,62–65. Our results also concurred
with other authors that racial and ethnic differences are an important risk factor. Wong
found that blacks had more than double the incidence in Caucasians79.
In addition to the covariates in our hypothesis, our results found male gender,
age between 65 and 74 years, lack of insurance and diagnosis before 2000 to give
higher risk of HCC late diagnosis. Male gender is a known risk factor of both incidence
60

and mortality of HCC as is evidenced in numerous studies 21,62,71 the mechanisms for
the increased risk may be through the absence of estrogen as has been shown by
McGlynn et al. who found that surgical menopause by bilateral oophorectomy increased
HCC risk in women80. Older age has been observed to increase the risk of HCC 21,71.
We also found a decreasing trend over time in the risk of HCC late-stage diagnoses,
which correspond to the global trend in liver cancer incidence 4,6,7,59. Our report showed
that county-level binge drinking increased the risk of late-stage HCC, as did Jee et al. in
Korea with individual alcohol intake ≥100g confering a 1.4-fold higher risk of HCC 11 and
Chuang et al. who reported 19%, 40% and 81% higher risk of HCC for 25, 50 and 100 g
of daily alcohol intake and believed there is no safe alcohol threshold for risk of
developing liver cancer 81. Consequently, the population with the highest late-stage
HCC risk in this Kentucky sample are the black, uninsured males aged 50 and older,
diagnosed before the year 2000 and living in counties with higher proportions of binge
drinking.
For the second paper (chapter 4), we hypothesied that early-stage diagnosis,
female gender and non-smoking status would confer a better liver cancer survival. Our
results showed that early stage at diagnosis and treatment were predictive of better
overall survival while early stage at diagnosis, year of diagnosis, non-smoking status
and treatment regimen were predictors for a better specific survival.
We did not find evidence that females had significantly lower mortality whether
all-cause or cause-specific than males, although we found that men and postmenopausal women had a similar risk, hinting at a possible role of sex hormones. A
protective effect of female gender on liver cancer all-cause mortality was found by

61

Artinyan et al., women having 8% less risk than men 82; Dong et al. showed that
females had lower risk of cause-specific mortality compared to men in a study of the
effect of alcohol use on HCC mortality 83.
Early-stage at diagnostic was a strong predictor of better all-cause and causespecific survival, reducing by more than half the risk of death. This finding is comparable
to the worsening survival of uninsured HCC cases diagnosed late in Tennessee found
by Zaydfudim et al. 78. Treatment regimen was strongly associated with survival. HCC
cases who recieved any type of treatment had better survival than their counterparts
with no treatment with surgical patients having a six-fold risk reduction. Other authors
have shown better HCC survival in patients eligible for surgery and chemotherapy
compared to other regimens 53,54,84. Our analysis shows a 20% increased risk of causespecific mortality in smokers. The role of smoking has been intensely investigated with
disimilar results. Our finding confirms that of Mangus et al. that smoking has a
worsening effect on HCC survival, with the risk increasing with increasing intake 85. On
the other hand, Raffetti et al. found that although smoking was associated with some
features predicting better survival, it did not have an effect on survival when also
considering the number of cigarettes smoked daily or the cumulative pack-year 86.
Finally, we showed that survival increased with time of diagnosis, confirming previous
findings of increasing survival rates attributed to earlier diagnosis and more eligibilty for
treatment 9,15,61,87.
The results from both papers should be beneficial to health care professionals in
the management of HCC in the state, whether in the design of targetted interventions to
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increase prevention or survival by increasing the number of early-stage diagnoses
which are eligible for more treatment options.

Implications for Public Health

According to the Center for Disease Control and Prevention, the public health

system is defined as “all public, private, and voluntary entities that contribute to the
delivery of essential public health services within a jurisdiction”88. In order to deliver
services of quality, public health professionals need to know all the determinants that
may influence a particular health problem within a particular population, that is at higher
risk. A population’s health is controlled by the five determinants of health that are
biological, socioeconomic, psychosocial, behavioral, or social in nature 89.
Through this capstone project, we endeavored to define the most sucesptible
population by assessing the influence of biology, behavior and socieconomic
environment on liver cancer in Kentucky. Liver cancer incidence and mortality rates
have been increaseing over the last two decades in the United States, with a significant
average annual percentage change of 2.7% (incidence) and 2.5% (mortality) 58,90. HCC
occurs mostly in older males with limited access to healthcare and low SES 47,68,78. This
capstone upholds previous findings and confim that the intervention efforts should be
targeted towards older black men, without health insurance and living in counties with
heavy alcohol use. Health professionals should focus screening efforts for an effective
surveillance to reduce late-stage diagnosis that may be beyond any therapeutic reach.
Furthermore, we must advocate for an universal health coverage to increase acces to
healthcare through policy change.
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More than 50% of patients in our series did not receive treatment and only 40%
had access to potentially curative treatment (surgery and chemotherapy). Previous
sudies have established how critical treatment is to the survival of HCC patients 52–
54,84,91.

With a mean survival time of only one year and less than 5% of patients

surviving after 5 years, epidemiologists should focus on studying the factors delaying
both early diagnosis and treatment in Kentuckians. The factors worsening the survival of
HCC patients should be made public so that awareness is raised among both the public
and health professions. Concurrently, to reverse the current trend of increasing HCC,
public health leaders should provide policy makers with results that trigger changes
leading to increased health coverage within the state and increased access to
healthcare for vulnerable populations.

Strenghts and limitations

This capstone has several strenghts. It is the first to assess the risk factors of

late-stage HCC and its survavibilty in Kentucky. Another strength is our data source.
The KCR is undeniably an excellent source of reliable and comprehensive data of HCC
cases in the State. While papers have explored extensively the risk of HCC incidence
and mortality, few investigated determining factors of late-stage diagnosis. Moreover,
survival studies have seldom researched the independent role of sex hormones on HCC
survival. This capstone aspired to fill the gap in knowledge.
Several limitations may impede the results of our research. The major limitation
is the lack of individual-level data concerning key covariates. SES was estimated
through county-level data of income, education and poverty level. With 120 counties in
the state, the results reported may have accounted for a lack of precision. Future
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studies should estimate at narrower level or better have access to individual data.
Likewise, alcohol intake, obesity and overweight status was evaluated at the countylevel, but their impact would have been more pertinent if these variables were
associated with individuals.
Viral hepatitis is a critical predictor of HCC and the fact that our series lacked
data on the infectious status of our cases was another limitation.

Recommendations

The state of Kentucky has a relatively homogenous racial and ethnic population

with most of the black population living in only two counties, Jefferson and Christian.
Therefore in this study it was difficult to assess the affect of race on HCC survival,
unlike the reports by other authors. Future research should explore HCC survival in
more heterogenous study populations.
SES has an important role in health and well-being of population, and its
interpretation is conditioned by the way it is defined. It is important to understand the
importance of SES and its interaction with race and ethnicity as well as its impact on
HCC risk. Future studies should design suitable measurement to account for all social
determinants of health.
With the continued increase in the incidence and mortality of HCC and given the
uncertainty around healthcare access, it is imperative to for researchers to study the
cost-effectiveness of care for the procurement of the best quality of HCC management
for Kentuckians.
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